Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585867 | 0.89 | NPC1 (0.77) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3583154 | 0.86 | SCD (0.76) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3584809 | 0.85 | SCD (0.82) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3585084 | 0.85 | SCD (1.00) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3583599 | 0.84 | SCD (0.70) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3577472 | 0.84 | SCD (0.73) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3591110 | 0.84 | SCD (0.73) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27706912 | 0.84 | SCD (0.66) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL243885 | 0.83 | SCD (0.65) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3589788 | 0.83 | SCD (0.71) | SCDRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| CN-101208089-A | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2008-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | SCD 1/4885RAB9A 2428/4885SMN1; SMN2 1323/4885 |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | SCD 1/4885RAB9A 2466/4885SMN1; SMN2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.